MIDDLE EAST RESPIRATORY SYNDROME CoV: AN EVOLVING VIRAL THREAT TO HUMAN HEALTH
Journal Title: International Research Journal of Pharmacy (IRJP) - Year 2015, Vol 6, Issue 12
Abstract
The Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease. It is caused by a novel single-stranded, positive-sense RNA betacoronavirus (MERS-CoV). Specific drug treatment exists for MERS and infection prevention and control measures are crucial to prevent spread in health-care facilities.The outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003, led to 8,422 cases and 916 deaths worldwide which highlighted the potential for newly emerging zoonotic coronaviruses to transmit from person one to another, especially in healthcare settings, and to cause severe human illness.MERS-CoV is a novel virus among the genus Betacoronavirus, which was initially identified in Saudi Arabia in September 2012, in two patients with severe pneumonia Upto 7 May 2013, the cases in France were identified, 30 cases had been confirmed as infected by the coronavirus worldwide which included four diagnosed in the United Kingdom (UK) and two in Germany. Two cases of severe respiratory infection have been confirmed as caused by a novel coronavirus. The case guideline has been issued by the World Health Organization (WHO) which is mainly based on acute respiratory illness, pneumonia and travel history. The incubation time is crucial as it is playing a major role in suspecting Saudi Arabia and Qatar, and define its clinical features. The presumed length of the incubation period was compared with known incubation periods of human coronavirus infections including that of severe acute respiratory syndrome (SARS).Our main aim of the article is to give overview on the MERS CoV disease pointing out its symptoms, diagnosis, spread, therapy and cases reported up to now. This is a uncommon virus and details about MERS is still unknown as it is often confused as some common viral respiratory disease so we have tried to collect the possible data and reports in our content.
Authors and Affiliations
Nikita Saraswat, Mohammad Faizan , Rituparna Palit, Pranay Wal
Keywords
Related Articles
- EP ID EP112017
- DOI 10.7897/2230-8407.0612152
- Views 92
- Downloads 0
DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF AMLODIPINE BESYLATE AND ENALAPRIL MALEATE
Stability testing is a routine procedure performed on drug substances and drug products to provide evidence on how the quality of a drug varies with time under the influence of a variety of parameters. Environmental fact...
DEVELOPMENT AND VALIDATION OF REVERSED-PHASE HPLC METHOD FOR ESTIMATION OF ONDANSETRON HYDROCHLORIDE IN BULK DRUG
A simple, accurate rapid and precise RP-HPLC method has been developed and validated for determination of Ondansetron hydrochloride in bulk drug. The RP-HPLC separation was achieved on hypersil C18 column (216 mm, 4.6 mm...
DESIGN DEVELOPMENT AND EVALUATION OF TRIMETAZIDINE DIHYDROCHLORIDE FLOATING BILAYER M.R TABLETS
Modified release tablet are coated or uncoated tablet containing auxiliary substance or prepared by the procedure that, separately or together are design to modify the rate or place at which the active ingredient are rel...
EVALUATION OF ANTIMICROBIAL AND ANTI-HISTAMINE ACTIVITY OF THE AERIAL PARTS OF TEPHROSIA PURPUREA L.
Tephrosia purpurea (Fabaceae) has been used as a medicinal plant in all over India. This plant is a much branched perennial herb. Roots are given orally against any type of poisoning such as snakebite and the aerial part...
A NOVEL EXPANDABLE CORE OF ELEMENTARY OSMOTIC PUMP: AN EFFECTIVE DEVICE FOR DELIVERY OF POORLY WATER-SOLUBLE DRUGS
The main intention of the present work is to design and evaluate a new Elementary Osmotic Pump (EOP) for efficient delivery of Poorly Water-Soluble Drugs (PWSDs). Drug release from the new system called Expandable EOP (...